google_counter
Treatment of acute myeloid leukemia (AML) with CAR T-cell therapy (666256) | University Hospital Tuebingen - BookingHealth
{"translation_price":"50","translation_doc_price":"40","child_coefficient":"1.1","transfer_price":"2.00","transfer_price_vip":"5.00","constant_transfer_price_vip":350,"constant_transfer_price":150,"constant_transfer_distanse":60,"type":"treatment","program_full_story":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Acute myeloid leukemia (AML) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient&#39;s medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p><strong>Day 3<\/strong>. Collecting patient&rsquo;s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient&#39;s own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div><div class=\"program_required_documents mt-4\"><h4>Required documents<\/h4><ul>\n\t<li>Complete blood count with white blood cell count<\/li>\n\t<li>Biochemical blood test (renal and liver function tests), if available<\/li>\n\t<li>Bone marrow biopsy results<\/li>\n\t<li>CT scan, if available<\/li>\n<\/ul>\n<\/div>","program_full_story_crm":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Acute myeloid leukemia (AML) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient&#39;s medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p><strong>Day 3<\/strong>. Collecting patient&rsquo;s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient&#39;s own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div>","is_ambulant":"0","bh_fee":"0","only_for_children":"0","no_service":"0","with_prepayment":"1","show_calculator":"1","paket_type":"1","btn_type":"0","clinic_icon":"6000458b4633b.jpg","city":"Tuebingen","clinic_site":"www.medizin.uni-tuebingen.de","department_recommend":"0","country":"Germany","country_id":"1","clinic_name":"University Hospital Tuebingen","cinic_name":"University Hospital Tuebingen","department_id":"3354","duration":"21","direction":"Hematology","min_duration":0,"clinic_id":"533","paketPrice":36000,"paket":"<ul>\n <li>Interpreter up to 80 hours<\/li>\n <li>Translation up to 15 pages<\/li>\n <li>Visa support<\/li>\n<\/ul>","title":"Treatment of acute myeloid leukemia (AML) with CAR T-cell therapy","price":{"val":579627.5,"type":"val"},"price_surcharge":0,"price_surcharge_clear":0,"extra_service_clinic":[{"id":"need_to_use_head_doctor","title":"Treatment by leading experts","type":"val","val":null,"req":0},{"id":"vip_person_room","title":"VIP room (whole period)","parent":"duration","type":"count_val","val":"80.00"},{"id":"1_person_room","title":" Single room (whole period)","parent":"duration","type":"count_val","val":"160.00"},{"id":"2_person_room","title":" double room (whole period)","parent":"duration","type":"count_val","val":"71.00"},{"id":"attendant_place","title":"Accommodation for the accompanying person ","parent":"duration","type":"count_val","val":"90.00"}],"extra_service":[],"translation_hours":"0","translation_doc_count":null,"roads":[{"id":"19","distance":"33","airport_title":"Stuttgart"},{"id":"2","distance":"244","airport_title":"Munich"},{"id":"6","distance":"262","airport_title":"Frankfurt a.M."}],"pakets":[],"lang":{"day":"Day","days":"days","ambulatory":"Outpatient","stationaryProgram":"Inpatient"}}

Treatment of acute myeloid leukemia (AML) with CAR T-cell therapy in University Hospital Tuebingen

University Hospital Tuebingen

Tuebingen, Germany
Program id # 666256
Doctor photo
Prof. Dr. med. Lothar Kanz
Department of Oncology, Hematology, Clinical Immunology, Rheumatology and Pulmonology
Specialized in: oncology, hematology, clinical immunology, rheumatology, pulmonology

The program includes:

  • Initial presentation in the clinic
  • Clinical history taking
  • Physical examination
  • Review of medical records
  • Laboratory tests:
    • Complete blood count
    • General urine analysis
    • Biochemical blood test (kidney and liver function tests)
    • Indicators of inflammation (CRP, ESR)
    • Indicators of blood coagulation
    • Immunohistochemical and genetic analysis of tumor cells (if indicated)
  • Leukapheresis, processing of T-cells and cultivation of CAR T-cells
  • Adjuvant chemotherapy
  • Infusion of modified CAR T-cells to a patient
  • Control examinations
  • Cost of essential medicines and materials
  • Nursing services
  • Full hospital accommodation
  • Explanation of future recommendations

Indications

  • Acute myeloid leukemia (AML) that is resistant to the conventional therapy

How program is carried out

Days 1-2. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.

Day 3. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.

Days 4-12. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.

Day 13. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.

Day 14 and other days. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.

Required documents

  • Complete blood count with white blood cell count
  • Biochemical blood test (renal and liver function tests), if available
  • Bone marrow biopsy results
  • CT scan, if available

Service

Price from:
Type of program :
Price for 1 day:
Expected duration of the program:
The minimum duration of the program:
Select

You may also book:

Hospital directly:
Saving:
Guarantee BookingHealth Price from:

About the department

The Department of Oncology, Hematology, Clinical Immunology, Rheumatology and Pulmonology at the University Hospital Tuebingen offers the full range of medical services in these fields. The department specializes in the treatment of lung, stomach and rectal cancer, sarcomas, therapy of malignant blood diseases using autologous and allogeneic stem cell transplantation, etc. In addition, in the field of autoimmune and rheumatological diseases, the department is one of the leading centers in Germany. The Chief Physician of the department is Prof. Dr. med. Lothar Kanz.

The cancer patients are offered the full range of systemic therapy, as well as other methods of treatment. In particular, the department specializes in bronchogenic lung cancer, metastatic colorectal cancer, advanced gastric cancer, sarcomas, etc. In the field of hematology, special focus is on the treatment of multiple myeloma, myelodysplastic syndrome, all types of leukemia, lymphomas, allogeneic and autologous bone marrow transplantation. Each patient receives an individual treatment program corresponding to the relevant international standards and protocols.

In the field of pulmonology, the department offers the treatment of all diseases of the lungs and respiratory tract. Particular attention is paid to the diagnostics/treatment of bronchogenic lung cancer. The Laboratory for Functional Diagnostics has all modern methods for the assessment of complaints associated with the respiratory system. For example, to assess lung function, the doctors use spirometry and the whole-body plethysmography, interventional bronchoscopy, etc. For the therapeutic purposes, bronchoscopy is used in respiratory tract occlusion due to the tumors and foreign bodies, pulmonary emphysema, etc.

In addition, the department has exceptional expertise in the field of immunological, rheumatological and autoimmune diseases. The department ranks among the leading European centers for the treatment of progressive systemic scleroderma. The department is proud to be the only center in Germany, which offers autologous stem cell transplantation for the treatment of this disease.

The diagnostic and therapeutic range of the department includes the following options:

  • Multiple myeloma
  • Lung cancer
  • Stomach and colon cancer
  • Myelodysplastic syndrome
  • All types of leukemia
  • Malignant lymphomas
  • Allogeneic stem cell transplantation, haploid stem cell transplantation
  • Sarcomas
  • Immunotherapy
  • Diagnostics and treatment of rheumatological diseases (for example, autologous stem cell transplantation in scleroderma, etc.)
  • Diagnostics and treatment of benign and malignant diseases of the lungs and respiratory tract (non-invasive ventilation, bronchoscopic lung biopsy, etc.)
  • Diagnostics and treatment of other diseases in the areas of specialization

Curriculum vitae

  • 1972 - 1978 Study of Medicine at the University of Freiburg.
  • 1978 Thesis defense on the subject: "Subcellular localization of prostaglandin synthase".
  • Internship in the Department of Internal Medicine at the University Hospital Freiburg.
  • 1985 - 1987 Specialization in Hematology/Oncology.
  • 1987 Doctoral thesis defense on the subject: "Human megakaryocyte progenitor cells".
  • 1994 Invitation to the position of (C4) Professor of Internal Medicine at the University of Hannover, then to the position of (C4) Professor of Internal Medicine at the Faculty of Medicine of the University of Tuebingen.
  • Since 1995, Medical Director of the Department of Oncology, Hematology, Clinical Immunology, Rheumatology and Pulmonology at the University Hospital Tuebingen.

Awards and Prizes

  • Goedecke Research Award of the University Hospital Tuebingen.
  • 1996 European Scientific Prize in Hematology.

Photo of the doctor: (c) Universitätsklinikum Tübingen 


About hospital

According to the prestigious medical publication Focus, the University Hospital Tuebingen ranks among the top five German hospitals! 

The hospital was founded in 1805, therefore it is proud of its long history, unique experience, and outstanding achievements in the field of medical care, as well as research and teaching activities. Nowadays, it is one of the most advanced medical institutions, which provides a wide range of general and highly specialized medical services. The hospital combines the state-of-art medical technologies in the field of diagnostics and the very latest treatment methods of a wide range of diseases.

The hospital has 17 specialized departments, which cover almost all fields of modern medicine and contribute to the top-class medical service in Germany. It treats about 367,000 outpatients and 74,000 inpatients annually. This testifies to the high authority of the hospital at the national and international medical arena. This is the first German hospital, which confirmed the high quality of healthcare and the effectiveness of service with a KTQ certification (in 2009).

Photo: (с) depositphotos

Accommodation in hospital

Patients rooms

The patients of the University Hospital Tuebingen live in comfortable single and double rooms with an ensuite bathroom equipped with a shower and toilet. The beds in the patient rooms are equipped with orthopedic mattresses that promote good and full sleep. There is a TV in the room, and it is also possible to connect a smartphone or laptop to the Internet. In addition, there is enough space in the patient room to receive 2-3 guests without inconvenience for the second patient.

The enhanced-comfort rooms include a hairdryer, heated towel rail, a large mirror, a direct dial telephone, a flat-screen satellite TV, a writing desk, free Internet access, a mini-bar and a refrigerator.

Meals and Menus

The patients of the hospital are offered tasty and healthy three meals a day: breakfast, lunch and dinner. Breakfast is served as a buffet, while for lunch and dinner there is a choice of several menus. Also, if desired, the patient will be provided with an individual menu. There are several cafes and cafeterias on the territory of the hospital, where one can have a tasty meal or enjoy a cup of coffee, tea and dessert.

Further details

Standard rooms include:

Toilet
Shower
Wi-Fi
TV

Religion

Religious services are available upon request.

Accompanying person

During the inpatient program, an accompanying person can stay with you in a patient room or in a hotel of your choice.

Hotel

During the outpatient program, you can stay in a hotel of your choice. Our managers will help you choose the most suitable option for you.